Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years  2.    CTCs provide distinct and impactful information that is not captured by circulating tumour DNA ...

Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including ...

Recognized in the Healthcare category of the 2025 Top Innovations contest, Haystack MRD® enables minimal residual disease ...

Detailed price information for Exact Sciences Cor (EXAS-Q) from The Globe and Mail including charting and trades.

Natera Inc. (($NTRA)) announced an update on their ongoing clinical study. Natera Inc. has initiated a new clinical study titled ‘Signatera-Guided ...

Personalis (($PSNL)) announced an update on their ongoing clinical study. Personalis Inc. is spearheading a pivotal clinical study titled ‘Breast ...

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

A major international study has found that a simple blood test may help doctors decide which patients with stage 3 colon ...

In MIBC patients, ctDNA-guided, adjuvant atezolizumab treatment is associated with significant survival improvements over placebo.

In patients with early-stage HER2-positive breast cancer in the DESTINY-Breast 05 and the DESTINY-Breast 11 trials, ...

From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...